Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics
Deciphera Pharmaceuticals, Inc. (DCPH)
Today's Latest Price: $55.19 USD
1.50 (2.79%)
Updated Jun 5 4:00pm
Add DCPH to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
DCPH Stock Summary
- DCPH's went public 2.69 years ago, making it older than just 8.45% of listed US stocks we're tracking.
- With a price/sales ratio of 123.01, Deciphera Pharmaceuticals Inc has a higher such ratio than 97.84% of stocks in our set.
- With a year-over-year growth in debt of 780.78%, Deciphera Pharmaceuticals Inc's debt growth rate surpasses 97.59% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Deciphera Pharmaceuticals Inc, a group of peers worth examining would be EIDX, RCUS, EPZM, SGMO, and NTLA.
- Visit DCPH's SEC page to see the company's official filings. To visit the company's web site, go to www.deciphera.com.
DCPH Daily Price Range
DCPH 52-Week Price Range
DCPH Stock Price Chart More Charts
DCPH Price/Volume Stats
| Current price | $55.19 | 52-week high | $71.11 |
| Prev. close | $53.69 | 52-week low | $19.88 |
| Day low | $54.06 | Volume | 542,121 |
| Day high | $56.46 | Avg. volume | 576,671 |
| 50-day MA | $50.61 | Dividend yield | N/A |
| 200-day MA | $49.28 | Market Cap | 3.08B |
Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio
Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.
Loading social stream, please wait...